《大行》里昂升石藥(1093.HK)目標價至17.4元 重申「跑贏大市」評級
里昂發表報告指,於前日(7月30日),石藥(1093.HK)與生物製藥公司Madrigal完成另一項交易,涉及GLP-1小分子藥物SYH2086,預付金額為1.2億美元,里程碑金額高達19.55億美元,另加按百分比計算的銷售權利金。
報告指,由於石藥有10個已上市的創新品牌及30多個將於2028年前推出的創新產品,預期其核心盈利增長將於2026年起重新加速。目標價由13.8元上調至17.4元。重申「高度確信跑贏大市」評級。
該行上調石藥2025至27年收入預測分別1.6%、14.3%及3%,純利預測分別上調11.8%、73.3%及11.6%,以反映對已完成及潛在授權項目的假設。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.